{
 "cells": [
  {
   "cell_type": "markdown",
   "id": "7ca1da3f-cf78-40f6-be57-f32cbc3695be",
   "metadata": {},
   "source": [
    "# RAG Evalaution on LegalBenchRAG\n",
    "\n",
    "- evaluation on dataset legalbenchrag\n",
    "- albert medium model and bge-m3 embedding\n",
    "- build the elastic search index with `python evalap/rag/build.py`"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "f33fde59-7aff-4f16-898d-95497d084548",
   "metadata": {},
   "outputs": [],
   "source": [
    "import os\n",
    "import sys\n",
    "import time\n",
    "from io import StringIO\n",
    "import concurrent.futures\n",
    "\n",
    "import dotenv\n",
    "from IPython.display import HTML\n",
    "import numpy as np\n",
    "import pandas as pd\n",
    "import requests\n",
    "from jinja2 import Template\n",
    "\n",
    "dotenv.load_dotenv(\"../.env\")\n",
    "\n",
    "EVALAP_API_URL = \"http://localhost:8000/v1\"\n",
    "EVALAP_API_KEY = os.getenv(\"EVALAP_API_KEY\")\n",
    "ALBERT_API_URL = \"https://albert.api.etalab.gouv.fr/v1\"\n",
    "ALBERT_API_KEY = os.getenv(\"ALBERT_API_KEY\")\n",
    "OPENAI_URL = \"https://api.openai.com/v1\"\n",
    "OPENAI_API_KEY = os.getenv(\"OPENAI_API_KEY\")\n",
    "headers = {\"Authorization\": f\"Bearer {EVALAP_API_KEY}\"}"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 2,
   "id": "64cb00e3-0309-4af1-b4e7-e92703de47c4",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>query</th>\n",
       "      <th>output_true</th>\n",
       "      <th>snippets</th>\n",
       "      <th>dataset_name</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>Consider the Marketing Affiliate Agreement bet...</td>\n",
       "      <td>This agreement shall begin upon the date of it...</td>\n",
       "      <td>[{'file_path': 'cuad/CybergyHoldingsInc_201405...</td>\n",
       "      <td>cuad</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>Consider the Marketing Affiliate Agreement bet...</td>\n",
       "      <td>This agreement shall begin upon the date of it...</td>\n",
       "      <td>[{'file_path': 'cuad/CybergyHoldingsInc_201405...</td>\n",
       "      <td>cuad</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>Consider the Marketing Affiliate Agreement bet...</td>\n",
       "      <td>This Agreement may be terminated by either par...</td>\n",
       "      <td>[{'file_path': 'cuad/CybergyHoldingsInc_201405...</td>\n",
       "      <td>cuad</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>Consider the Marketing Affiliate Agreement bet...</td>\n",
       "      <td>This Agreement is accepted by Company in the S...</td>\n",
       "      <td>[{'file_path': 'cuad/CybergyHoldingsInc_201405...</td>\n",
       "      <td>cuad</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>Consider the Marketing Affiliate Agreement bet...</td>\n",
       "      <td>MA may not assign, sell, lease or otherwise tr...</td>\n",
       "      <td>[{'file_path': 'cuad/CybergyHoldingsInc_201405...</td>\n",
       "      <td>cuad</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>...</th>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>6884</th>\n",
       "      <td>Consider VELCO's Non-Disclosure Agreement; Doe...</td>\n",
       "      <td>For purposes of this Agreement, “BCSI” shall m...</td>\n",
       "      <td>[{'file_path': 'contractnli/VELCO%20NDA%20rev0...</td>\n",
       "      <td>contractnli</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>6885</th>\n",
       "      <td>Consider VELCO's Non-Disclosure Agreement; Doe...</td>\n",
       "      <td>The foregoing notwithstanding, the Recipient m...</td>\n",
       "      <td>[{'file_path': 'contractnli/VELCO%20NDA%20rev0...</td>\n",
       "      <td>contractnli</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>6886</th>\n",
       "      <td>Consider VELCO's Non-Disclosure Agreement; Doe...</td>\n",
       "      <td>5. In the event that the Recipient is required...</td>\n",
       "      <td>[{'file_path': 'contractnli/VELCO%20NDA%20rev0...</td>\n",
       "      <td>contractnli</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>6887</th>\n",
       "      <td>Consider VELCO's Non-Disclosure Agreement; Doe...</td>\n",
       "      <td>The foregoing notwithstanding, the Recipient m...</td>\n",
       "      <td>[{'file_path': 'contractnli/VELCO%20NDA%20rev0...</td>\n",
       "      <td>contractnli</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>6888</th>\n",
       "      <td>Consider VELCO's Non-Disclosure Agreement; Doe...</td>\n",
       "      <td>4. Recipient and each of its Representatives s...</td>\n",
       "      <td>[{'file_path': 'contractnli/VELCO%20NDA%20rev0...</td>\n",
       "      <td>contractnli</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "<p>6889 rows × 4 columns</p>\n",
       "</div>"
      ],
      "text/plain": [
       "                                                  query  \\\n",
       "0     Consider the Marketing Affiliate Agreement bet...   \n",
       "1     Consider the Marketing Affiliate Agreement bet...   \n",
       "2     Consider the Marketing Affiliate Agreement bet...   \n",
       "3     Consider the Marketing Affiliate Agreement bet...   \n",
       "4     Consider the Marketing Affiliate Agreement bet...   \n",
       "...                                                 ...   \n",
       "6884  Consider VELCO's Non-Disclosure Agreement; Doe...   \n",
       "6885  Consider VELCO's Non-Disclosure Agreement; Doe...   \n",
       "6886  Consider VELCO's Non-Disclosure Agreement; Doe...   \n",
       "6887  Consider VELCO's Non-Disclosure Agreement; Doe...   \n",
       "6888  Consider VELCO's Non-Disclosure Agreement; Doe...   \n",
       "\n",
       "                                            output_true  \\\n",
       "0     This agreement shall begin upon the date of it...   \n",
       "1     This agreement shall begin upon the date of it...   \n",
       "2     This Agreement may be terminated by either par...   \n",
       "3     This Agreement is accepted by Company in the S...   \n",
       "4     MA may not assign, sell, lease or otherwise tr...   \n",
       "...                                                 ...   \n",
       "6884  For purposes of this Agreement, “BCSI” shall m...   \n",
       "6885  The foregoing notwithstanding, the Recipient m...   \n",
       "6886  5. In the event that the Recipient is required...   \n",
       "6887  The foregoing notwithstanding, the Recipient m...   \n",
       "6888  4. Recipient and each of its Representatives s...   \n",
       "\n",
       "                                               snippets dataset_name  \n",
       "0     [{'file_path': 'cuad/CybergyHoldingsInc_201405...         cuad  \n",
       "1     [{'file_path': 'cuad/CybergyHoldingsInc_201405...         cuad  \n",
       "2     [{'file_path': 'cuad/CybergyHoldingsInc_201405...         cuad  \n",
       "3     [{'file_path': 'cuad/CybergyHoldingsInc_201405...         cuad  \n",
       "4     [{'file_path': 'cuad/CybergyHoldingsInc_201405...         cuad  \n",
       "...                                                 ...          ...  \n",
       "6884  [{'file_path': 'contractnli/VELCO%20NDA%20rev0...  contractnli  \n",
       "6885  [{'file_path': 'contractnli/VELCO%20NDA%20rev0...  contractnli  \n",
       "6886  [{'file_path': 'contractnli/VELCO%20NDA%20rev0...  contractnli  \n",
       "6887  [{'file_path': 'contractnli/VELCO%20NDA%20rev0...  contractnli  \n",
       "6888  [{'file_path': 'contractnli/VELCO%20NDA%20rev0...  contractnli  \n",
       "\n",
       "[6889 rows x 4 columns]"
      ]
     },
     "execution_count": 2,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "# Fetch the dataset from Evalap\n",
    "# --\n",
    "dataset_name = \"LegalBenchRAG\"\n",
    "response = requests.get(\n",
    "    f\"{EVALAP_API_URL}/dataset?name={dataset_name}&with_df=true\",\n",
    "    headers={\"Authorization\": f\"Bearer {EVALAP_API_KEY}\"},\n",
    ")\n",
    "response.raise_for_status()\n",
    "dataset = response.json()\n",
    "dataset_df =  pd.read_json(StringIO(dataset[\"df\"]))\n",
    "dataset_df"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "474ad967-2543-4f4d-91d0-24abe091d9fd",
   "metadata": {},
   "outputs": [],
   "source": [
    "# Build 1000 random index to work with a subset of the dataset in order to do faster and cheaper evaluation\n",
    "# --\n",
    "N = len(dataset_df) # Size of the\n",
    "rng = np.random.default_rng(42)\n",
    "sample = rng.choice(np.arange(N), size=1000, replace=False)\n",
    "sample = sample.tolist()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 129,
   "id": "0867c195-260b-4d93-9abc-2337c9ba7c45",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Created expset: LegalBenchRAG Evaluation (111)\n"
     ]
    }
   ],
   "source": [
    "# Initial NORAG experiments\n",
    "# --\n",
    "\n",
    "expset_name = \"LegalBenchRAG Evaluation\"\n",
    "expset_readme = \"A extensive RAG evaluation on the LegalBenchRAG dataset. See [complete me]\"\n",
    "\n",
    "system_prompt = \"Provide a clear and sound answer to the question. Use the source of information, if given, to answer.\"\n",
    "sampling_params = {\"temperature\": 0.2}\n",
    "\n",
    "common_params = {\n",
    "    \"dataset\": dataset[\"name\"],\n",
    "    \"metrics\": [\"judge_precision\", \"output_length\"],\n",
    "    \"model\": {\"sampling_params\" : sampling_params, \"system_prompt\": system_prompt},\n",
    "    \"judge_model\": {\n",
    "        \"name\": \"mistralai/Mistral-Small-3.2-24B-Instruct-2506\", \"base_url\": ALBERT_API_URL, \"api_key\": ALBERT_API_KEY\n",
    "    },\n",
    "    \"sample\": sample,\n",
    "}\n",
    "\n",
    "grid_params = {\n",
    "    \"model\": [\n",
    "        {\"name\": \"mistralai/Mistral-Small-3.2-24B-Instruct-2506\", \"base_url\": ALBERT_API_URL, \"api_key\": ALBERT_API_KEY}\n",
    "    ],\n",
    "}\n",
    "\n",
    "expset = {\n",
    "    \"name\": expset_name,\n",
    "    \"readme\": expset_readme,\n",
    "    \"cv\": {\"common_params\": common_params, \"grid_params\": grid_params, \"repeat\": 1},\n",
    "}\n",
    "\n",
    "response = requests.post(\n",
    "    f\"{EVALAP_API_URL}/experiment_set\",\n",
    "    headers={\"Authorization\": f\"Bearer {EVALAP_API_KEY}\", \"Content-Encoding\": \"gzip\"},\n",
    "    json=expset,\n",
    ")\n",
    "resp = response.json()\n",
    "if \"id\" in resp:\n",
    "    expset_id = resp[\"id\"]\n",
    "    print(f'Created expset: {resp[\"name\"]} ({resp[\"id\"]})')\n",
    "else:\n",
    "    print(resp)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "7c5d819c-d820-4584-ad9d-c9ec04a2d443",
   "metadata": {},
   "outputs": [],
   "source": [
    "# add the evalap repo into the workspace\n",
    "# @FUTURE: !pip install evalap\n",
    "sys.path.append(\"../\")\n",
    "from evalap.clients.llm import LlmClient, split_think_answer\n",
    "from evalap.rag.search import SearchEngineClient\n",
    "\n",
    "\n",
    "rag_prompt = Template(\"\"\"Use the following sources of information as a source of truth if they address the question:\n",
    "\n",
    "<SOURCE>\n",
    "{% for chunk in chunks %}\n",
    "{{chunk.text}}\n",
    "\n",
    "---\n",
    "\n",
    "{% endfor %}\n",
    "</SOURCE>\n",
    "\n",
    "QUESTION:\n",
    "{{query}}\n",
    "\"\"\")\n",
    "\n",
    "def rerank(prompt: str, hits: list[str], model=None) -> list[str]:\n",
    "    \"\"\"\n",
    "    Reranks a list of documents based on their relevance to the prompt.\n",
    "\n",
    "    Args:\n",
    "        prompt: The query or question to rerank documents against\n",
    "        hits: List of document texts to rerank\n",
    "        model: Optional model name to use for reranking (uses default if None)\n",
    "\n",
    "    Returns:\n",
    "        A reordered list of the input documents, sorted by relevance\n",
    "    \"\"\"\n",
    "    # API endpoint (replace with your actual endpoint)\n",
    "    url = \"https://albert.api.etalab.gouv.fr/v1/rerank\"\n",
    "\n",
    "    # Prepare the request payload\n",
    "    payload = {\"prompt\": prompt, \"input\": hits, \"model\": model}\n",
    "\n",
    "    # Set headers\n",
    "    headers = {\"Content-Type\": \"application/json\", \"Authorization\": f\"Bearer {os.getenv('ALBERT_API_KEY')}\"}\n",
    "\n",
    "    # Send the request\n",
    "    response = requests.post(url, headers=headers, json=payload)\n",
    "    response.raise_for_status()\n",
    "    result = response.json()\n",
    "\n",
    "    # Extract the scores and indices\n",
    "    scored_indices = result[\"data\"]\n",
    "\n",
    "    # Sort the indices by score in descending order (higher score = more relevant)\n",
    "    sorted_indices = sorted(scored_indices, key=lambda x: x.get(\"score\", 0), reverse=True)\n",
    "\n",
    "    # Reorder the original hits list based on the sorted indices\n",
    "    reranked_hits = []\n",
    "    for item in sorted_indices:\n",
    "        index = item.get(\"index\", 0)\n",
    "        if 0 <= index < len(hits):\n",
    "            reranked_hits.append(hits[index])\n",
    "\n",
    "    return reranked_hits\n",
    "\n",
    "# Augment a prompt with collection search\n",
    "def do_rag(query, collection_name=None, limit=5, search_method=\"hybrid\", model_embedding=None, model_rerank=None):\n",
    "    # Search relevant chunks\n",
    "    se_client = SearchEngineClient()\n",
    "    if model_rerank:\n",
    "        limit_ = limit * 2\n",
    "    else:\n",
    "        limit_ = limit\n",
    "    hits = se_client.search(collection_name, query, limit=limit_, method=search_method, model_embedding=model_embedding)\n",
    "    if model_rerank:\n",
    "        # albert reranker only...\n",
    "        _hits = rerank(query, [h[\"text\"] for h in hits], model=model_rerank)\n",
    "        for i, h in enumerate(_hits):\n",
    "            hits[i][\"text\"] = h\n",
    "        hits = hits[:limit]\n",
    "\n",
    "    # Render prompt\n",
    "    return rag_prompt.render(query=query, chunks=hits, limit=limit)\n",
    "\n",
    "# The LLM core generation\n",
    "def generate_with_rag(prompt, model=None, system_prompt=system_prompt, with_rag=True, sampling_params=None, **rag_params):\n",
    "    if not sampling_params:\n",
    "        sampling_params = {}\n",
    "\n",
    "    if with_rag:\n",
    "        prompt = do_rag(prompt, **rag_params)\n",
    "\n",
    "    messages = [{\"role\": \"user\", \"content\": prompt}]\n",
    "    if system_prompt:\n",
    "        messages = [{\"role\": \"system\", \"content\": system_prompt}] + messages\n",
    "\n",
    "    aiclient = LlmClient()\n",
    "    result = aiclient.generate(model=model, messages=messages, **sampling_params)\n",
    "    observation = result.choices[0].message.content\n",
    "    think, answer = split_think_answer(observation)\n",
    "    return answer\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 17,
   "id": "225d7fe1-b079-4903-8982-6a36e35d4c41",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "[{'text': '1\\n\\nSource: CNS PHARMACEUTICALS, INC., 8-K, 3/26/2020', '__score': 0.7200798}, {'text': '2\\n\\nSource: CNS PHARMACEUTICALS, INC., 8-K, 3/26/2020', '__score': 0.7199438}, {'text': '4\\n\\nSource: CNS PHARMACEUTICALS, INC., 8-K, 3/26/2020', '__score': 0.71921223}]\n"
     ]
    },
    {
     "data": {
      "text/plain": [
       "['4\\n\\nSource: CNS PHARMACEUTICALS, INC., 8-K, 3/26/2020',\n",
       " '1\\n\\nSource: CNS PHARMACEUTICALS, INC., 8-K, 3/26/2020',\n",
       " '2\\n\\nSource: CNS PHARMACEUTICALS, INC., 8-K, 3/26/2020']"
      ]
     },
     "execution_count": 17,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "se_client = SearchEngineClient()\n",
    "hits = se_client.search(\"legalbenchrag_v2\", \"CNI\", limit=3, method=\"semantic\", model_embedding=\"BAAI/bge-m3\")\n",
    "#hits = se_client.search(\"legalbenchrag_v4\", \"CNI\", limit=3, method=\"hybrid\", model_embedding=\"qwen3-embedding-8b\")\n",
    "print(hits)\n",
    "hits = rerank(\"CNI\", [h[\"text\"] for h in hits], model=\"BAAI/bge-reranker-v2-m3\")\n",
    "hits"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 8,
   "id": "31b924c1-0f80-4f89-a266-07bafe389364",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Use the following sources of information as a source of truth if they address the question:\n",
      "\n",
      "<SOURCE>\n",
      "\n",
      "<intro>\n",
      "Exhibit 10.1 Development Agreement This Development Agreement (the \"Agreement\") dated as of March 20, 2020 (the \"Effective Date\") is entered into by and between CNS Pharmaceuticals, Inc. (\"CNS\"), a Nevada corporation, having a business address of 2100 West Loop South, Suite 900, Houston, Texas 77027, and WPD Pharmaceuticals, (\"WPD\"), a Polish corporation, having a business address of ul. Żwirki i Wigury 101, 02-089 Warszawa. CNS and WPD are sometimes referred to herein individually as a \"Party\" and collectively as the \"Parties.\" RECITALS WHEREAS, WPD is party to a sublicense agreement dated February 19, 2019 with Moleculin Biotech, Inc. (\"MBI\") (the \"Sublicense Agreement\") to research and develop, manufacture, have manufactured, use, export/import, offer to sell and/or sell certain products for use in certain territories; WHEREAS, WPD is developing certain anti-viral indications pursuant to the Sublicense Agreement; and WHEREAS, CNS has agreed to fund a portion of the development of such indications in exchange for certain economic rights. NOW, THEREFORE, in consideration of the covenants, conditions and agreements hereinafter set forth, and other valuable consideration, the receipt and sufficiency of which is hereby acknowledged, WPD and CNS hereby agree as follows: ARTICLE 1 DEFINITIONS 1.1 \"Approval Achievement Date\" means the earlier of the: (i) date on which WPD receives marketing approval for a Development Product in one-half of the countries included in the Sublicensed Territory, as defined in the Sublicense Agreement; or (ii) the payment by WPD to CNS of Development Fees hereunder of $1.0 million. 1.2 \"Business Day\" means any day other than a day which is a Saturday, a Sunday or any other day on which banks are authorized or required to be closed in New York City, NY. 1.3 \"Calendar Quarter\" means the consecutive three month period ending on one of March 31, June 30, September 30, or December 31. 1.4 \"Confidential Information\" includes: (1) all information contained in documents marked \"confidential\" and disclosed by one Party (the \"disclosing party\") to the other Party (the \"recipient party\") pursuant to this Agreement; (2) orally disclosed information which is disclosed by the disclosing party to the recipient party pursuant to this Agreement, summarized in writing, identified as \"confidential\" and delivered to the recipient party; and (3) all proprietary technical information, business and financial information, and all other information which a reasonable person would treat confidentially that relates to the Development Products and disclosed from the disclosing party to the recipient party, whether or not the information is marked as \"confidential.\" Notwithstanding anything to the contrary, CNS shall be permitted to make such disclosures as CNS determines, in its sole discretion, is required pursuant to the Securities Exchange Act of 1934, as amended, and the rules and regulations thereof. 1.5 \"Development Fee\" means 50% of the Net Sales for any Development Products in the Development Territory. 1.6 \"Development Products\" means: (i) Sublicensed Products, as defined in the Sublicense Agreement, in the field of pharmaceutical drug products for the treatment of any viral infection in humans; and (ii) any other drug or product in the field of pharmaceutical drug products for the treatment of any viral infection in humans that is licensed between WPD and MBI after this date. 1.7 \"Development Territory\" means (i) until the Approval Achievement Date, the Sublicensed Territory, as defined in the Sublicense Agreement; and (ii) after the Approval Achievement Date, the Sublicensed Territory, as defined in the Sublicense Agreement, other than Poland.\n",
      "</intro>\n",
      "<passage>\n",
      "1.8 \"Net Sales\" shall be defined in the same way as defined in Sections 6.1 (a)-(f) of the Sublicense Agreement, as applicable only to the relevant Development Products less any \"pass-thru royalties\" or \"override royalty percentage\" paid by WPD pursuant to the Sublicense Agreement. 1.9 \"Phase II Milestone Payment\" means the completion by WPD of a Phase II Study in one of the countries included within the Development Territory, which clinical trial meets all endpoints and is sufficient to form the basis of an application for approval of a Development Product in one Development Territory other than Poland. 1.10 \"Sale\", \"Sells\", \"Sold\" means the transfer or disposition of a Development Product, for value, to a person or entity for end use. ARTICLE 2 DEVELOPMENT AGREEMENT 2.1 Subject to the terms and conditions of this Agreement, WPD hereby agrees to use its commercially reasonable efforts in good faith to take, or cause to be taken, all actions, and to do or cause to be done, all things necessary, proper or desirable or advisable under applicable laws to develop and commercialize the Development Products, with a goal of eventual approval of Development Products in the Development Territory. In exchange for the payment by WPD of the Development Fee to CNS, CNS hereby agrees to pay WPD the following payments: (i) within thirty Business Days from the date of this Agreement, CNS will make an upfront payment of $225,000 to WPD; and (ii) within thirty days of the verified achievement of the Phase II Milestone, (such verification shall be conducted by an independent third party mutually acceptable to the parties hereto), CNS will make a payment of $775,000 to WPD. 2.2 If after three years from the Effective Date of this Development Agreement, WPD fails to use commercially reasonable efforts as set forth in section 2.1 above, CNS shall have the right to terminate this Agreement pursuant to the terms specified in Section 6.2 below, and CNS shall be entitled to the return of any payments made hereunder. For the purpose of this clause, if WPD has expended the funds provided by CNS pursuant to section 2.1 above on developing anti-viral indications (including all direct and indirect costs of such development), it will be deemed to have used commercially reasonable efforts in good faith. 2.3 The first Development Fees payment shall be due forty-five days after the end of the Calendar Quarter in which the first Sale of a Development Product took place. Thereafter, WPD shall furnish to CNS Development Fees no later than forty-five days after the end of each Calendar Quarter for the Sale of Development Products through the end of such Calendar Quarter and shall further furnish CNS with a written statement setting forth an accounting showing the calculation of the Development Fees. ARTICLE 3 INFORMATION AND USE 3.1 WPD shall furnish CNS with written reports summarizing the progress of the research and development conducted under the Sublicense Agreement related to the Development Products on a quarterly basis. 3.2 The Parties agree to a mutual exchange of any data, information or know-how resulting from the research and development of the Development Products. ARTICLE 4 OTHER COMPENSATION 4.1 If MBI exercises its right to terminate the Sublicense Agreement in whole, or to remove a portion of the sublicensed subject matter that relates to some or all of the Development Products, by paying to WPD the Buyback Consideration (as defined in the Sublicense Agreement), WPD agrees that CNS shall receive the greater of (i) 50% of the Buyback Consideration that is attributable to the field of anti-viral pharmaceutical drug products for humans (such attribution to be mutually agreed upon by the Parties), and (ii) the amounts actually provided to WPD pursuant to Section 2.1 of this Agreement.\n",
      "</passage>\n",
      "\n",
      "---\n",
      "\n",
      "\n",
      "<intro>\n",
      "Exhibit 10.1 Development Agreement This Development Agreement (the \"Agreement\") dated as of March 20, 2020 (the \"Effective Date\") is entered into by and between CNS Pharmaceuticals, Inc. (\"CNS\"), a Nevada corporation, having a business address of 2100 West Loop South, Suite 900, Houston, Texas 77027, and WPD Pharmaceuticals, (\"WPD\"), a Polish corporation, having a business address of ul. Żwirki i Wigury 101, 02-089 Warszawa. CNS and WPD are sometimes referred to herein individually as a \"Party\" and collectively as the \"Parties.\" RECITALS WHEREAS, WPD is party to a sublicense agreement dated February 19, 2019 with Moleculin Biotech, Inc. (\"MBI\") (the \"Sublicense Agreement\") to research and develop, manufacture, have manufactured, use, export/import, offer to sell and/or sell certain products for use in certain territories; WHEREAS, WPD is developing certain anti-viral indications pursuant to the Sublicense Agreement; and WHEREAS, CNS has agreed to fund a portion of the development of such indications in exchange for certain economic rights. NOW, THEREFORE, in consideration of the covenants, conditions and agreements hereinafter set forth, and other valuable consideration, the receipt and sufficiency of which is hereby acknowledged, WPD and CNS hereby agree as follows: ARTICLE 1 DEFINITIONS 1.1 \"Approval Achievement Date\" means the earlier of the: (i) date on which WPD receives marketing approval for a Development Product in one-half of the countries included in the Sublicensed Territory, as defined in the Sublicense Agreement; or (ii) the payment by WPD to CNS of Development Fees hereunder of $1.0 million. 1.2 \"Business Day\" means any day other than a day which is a Saturday, a Sunday or any other day on which banks are authorized or required to be closed in New York City, NY. 1.3 \"Calendar Quarter\" means the consecutive three month period ending on one of March 31, June 30, September 30, or December 31. 1.4 \"Confidential Information\" includes: (1) all information contained in documents marked \"confidential\" and disclosed by one Party (the \"disclosing party\") to the other Party (the \"recipient party\") pursuant to this Agreement; (2) orally disclosed information which is disclosed by the disclosing party to the recipient party pursuant to this Agreement, summarized in writing, identified as \"confidential\" and delivered to the recipient party; and (3) all proprietary technical information, business and financial information, and all other information which a reasonable person would treat confidentially that relates to the Development Products and disclosed from the disclosing party to the recipient party, whether or not the information is marked as \"confidential.\" Notwithstanding anything to the contrary, CNS shall be permitted to make such disclosures as CNS determines, in its sole discretion, is required pursuant to the Securities Exchange Act of 1934, as amended, and the rules and regulations thereof. 1.5 \"Development Fee\" means 50% of the Net Sales for any Development Products in the Development Territory. 1.6 \"Development Products\" means: (i) Sublicensed Products, as defined in the Sublicense Agreement, in the field of pharmaceutical drug products for the treatment of any viral infection in humans; and (ii) any other drug or product in the field of pharmaceutical drug products for the treatment of any viral infection in humans that is licensed between WPD and MBI after this date. 1.7 \"Development Territory\" means (i) until the Approval Achievement Date, the Sublicensed Territory, as defined in the Sublicense Agreement; and (ii) after the Approval Achievement Date, the Sublicensed Territory, as defined in the Sublicense Agreement, other than Poland.\n",
      "</intro>\n",
      "<passage>\n",
      "1\n",
      "\n",
      "Source: CNS PHARMACEUTICALS, INC., 8-K, 3/26/2020\n",
      "</passage>\n",
      "\n",
      "---\n",
      "\n",
      "\n",
      "<intro>\n",
      "Exhibit 10.1 Development Agreement This Development Agreement (the \"Agreement\") dated as of March 20, 2020 (the \"Effective Date\") is entered into by and between CNS Pharmaceuticals, Inc. (\"CNS\"), a Nevada corporation, having a business address of 2100 West Loop South, Suite 900, Houston, Texas 77027, and WPD Pharmaceuticals, (\"WPD\"), a Polish corporation, having a business address of ul. Żwirki i Wigury 101, 02-089 Warszawa. CNS and WPD are sometimes referred to herein individually as a \"Party\" and collectively as the \"Parties.\" RECITALS WHEREAS, WPD is party to a sublicense agreement dated February 19, 2019 with Moleculin Biotech, Inc. (\"MBI\") (the \"Sublicense Agreement\") to research and develop, manufacture, have manufactured, use, export/import, offer to sell and/or sell certain products for use in certain territories; WHEREAS, WPD is developing certain anti-viral indications pursuant to the Sublicense Agreement; and WHEREAS, CNS has agreed to fund a portion of the development of such indications in exchange for certain economic rights. NOW, THEREFORE, in consideration of the covenants, conditions and agreements hereinafter set forth, and other valuable consideration, the receipt and sufficiency of which is hereby acknowledged, WPD and CNS hereby agree as follows: ARTICLE 1 DEFINITIONS 1.1 \"Approval Achievement Date\" means the earlier of the: (i) date on which WPD receives marketing approval for a Development Product in one-half of the countries included in the Sublicensed Territory, as defined in the Sublicense Agreement; or (ii) the payment by WPD to CNS of Development Fees hereunder of $1.0 million. 1.2 \"Business Day\" means any day other than a day which is a Saturday, a Sunday or any other day on which banks are authorized or required to be closed in New York City, NY. 1.3 \"Calendar Quarter\" means the consecutive three month period ending on one of March 31, June 30, September 30, or December 31. 1.4 \"Confidential Information\" includes: (1) all information contained in documents marked \"confidential\" and disclosed by one Party (the \"disclosing party\") to the other Party (the \"recipient party\") pursuant to this Agreement; (2) orally disclosed information which is disclosed by the disclosing party to the recipient party pursuant to this Agreement, summarized in writing, identified as \"confidential\" and delivered to the recipient party; and (3) all proprietary technical information, business and financial information, and all other information which a reasonable person would treat confidentially that relates to the Development Products and disclosed from the disclosing party to the recipient party, whether or not the information is marked as \"confidential.\" Notwithstanding anything to the contrary, CNS shall be permitted to make such disclosures as CNS determines, in its sole discretion, is required pursuant to the Securities Exchange Act of 1934, as amended, and the rules and regulations thereof. 1.5 \"Development Fee\" means 50% of the Net Sales for any Development Products in the Development Territory. 1.6 \"Development Products\" means: (i) Sublicensed Products, as defined in the Sublicense Agreement, in the field of pharmaceutical drug products for the treatment of any viral infection in humans; and (ii) any other drug or product in the field of pharmaceutical drug products for the treatment of any viral infection in humans that is licensed between WPD and MBI after this date. 1.7 \"Development Territory\" means (i) until the Approval Achievement Date, the Sublicensed Territory, as defined in the Sublicense Agreement; and (ii) after the Approval Achievement Date, the Sublicensed Territory, as defined in the Sublicense Agreement, other than Poland.\n",
      "</intro>\n",
      "<passage>\n",
      "4\n",
      "\n",
      "Source: CNS PHARMACEUTICALS, INC., 8-K, 3/26/2020\n",
      "</passage>\n",
      "\n",
      "---\n",
      "\n",
      "\n",
      "</SOURCE>\n",
      "\n",
      "QUESTION: \n",
      "CNI\n"
     ]
    }
   ],
   "source": [
    "print(do_rag(\"CNI\", collection_name=\"legalbenchrag_v3\", model_embedding=\"BAAI/bge-m3\", limit=3, model_rerank=\"BAAI/bge-reranker-v2-m3\"))"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "c44dfa6c-61c3-4bda-bd42-a17e9611b3ca",
   "metadata": {},
   "outputs": [],
   "source": [
    "# Async computing -- RAG generation\n",
    "# --\n",
    "from functools import partial\n",
    "\n",
    "\"\"\"\n",
    "sans \"lbrv\": simple chunking\n",
    "k: 10, lw: 1, sw: 1.5\n",
    "\n",
    "lbrv2: simple chunking\n",
    "k: 40, lw: 0.5, sw: 1\n",
    "\n",
    "lbrv2.5: simple chunking\n",
    "k: 50, lw: 1, sw: 1\n",
    "\n",
    "lbrv3: simple chunking\n",
    "k: 60, lw: 1, sw: 1.5\n",
    "\n",
    "lbvrv4: header chunking\n",
    "k20, lw: 1, sw: 1.5\n",
    "\n",
    "v4.5: header chunking\n",
    "k:2, lw: 1, sw: 1.5\n",
    "\n",
    "v4.6: header chunking\n",
    "k:10, lw: 1, sw: 1.5 (best)\n",
    "\n",
    "v5: header chunking + reranker\n",
    "k:10, lw: 1, sw: 1.5\n",
    "\"\"\"\n",
    "\n",
    "# The models to runs\n",
    "models = [\n",
    "    #{\n",
    "    # \"aliased_name\": \"model_hybrid_7_qwen3_lbrv4.6\",\n",
    "    # \"model\": \"mistralai/Mistral-Small-3.2-24B-Instruct-2506\",\n",
    "    # \"collection_name\": \"legalbenchrag_v4\",\n",
    "    # \"model_embedding\": \"qwen3-embedding-8b\",\n",
    "    # \"search_method\": \"hybrid\",\n",
    "    # \"limit\": 7,\n",
    "    # \"system_prompt\": system_prompt,\n",
    "    # \"sampling_params\": sampling_params,\n",
    "    #},\n",
    "    #{\n",
    "    # \"aliased_name\": \"model_semantic_20_qwen3_lbrv4.6\",\n",
    "    # \"model\": \"mistralai/Mistral-Small-3.2-24B-Instruct-2506\",\n",
    "    # \"collection_name\": \"legalbenchrag_v4\",\n",
    "    # \"model_embedding\": \"qwen3-embedding-8b\",\n",
    "    # \"search_method\": \"semantic\",\n",
    "    # \"limit\": 20,\n",
    "    # \"system_prompt\": system_prompt,\n",
    "    # \"sampling_params\": sampling_params,\n",
    "    #},\n",
    "   {\n",
    "     \"aliased_name\": \"model_hybrid_7_qwen3_lbrv5\",\n",
    "     \"model\": \"mistralai/Mistral-Small-3.2-24B-Instruct-2506\",\n",
    "     \"collection_name\": \"legalbenchrag_v4\",\n",
    "     \"model_embedding\": \"qwen3-embedding-8b\",\n",
    "     \"model_rerank\": \"BAAI/bge-reranker-v2-m3\",\n",
    "     \"search_method\": \"hybrid\",\n",
    "     \"limit\": 7,\n",
    "     \"system_prompt\": system_prompt,\n",
    "     \"sampling_params\": sampling_params,\n",
    "    },\n",
    "    {\n",
    "     \"aliased_name\": \"model_semantic_20_qwen3_lbrv5\",\n",
    "     \"model\": \"mistralai/Mistral-Small-3.2-24B-Instruct-2506\",\n",
    "     \"collection_name\": \"legalbenchrag_v4\",\n",
    "     \"model_embedding\": \"qwen3-embedding-8b\",\n",
    "     \"model_rerank\": \"BAAI/bge-reranker-v2-m3\",\n",
    "     \"search_method\": \"semantic\",\n",
    "     \"limit\": 20,\n",
    "     \"system_prompt\": system_prompt,\n",
    "     \"sampling_params\": sampling_params,\n",
    "    },\n",
    "\n",
    "]\n",
    "\n",
    "# Loop over the model to try\n",
    "model_answers = []\n",
    "for model in models:\n",
    "    # Create a list of model arguments (same model repeated for each prompt)\n",
    "    prompts = dataset_df.iloc[sample]['query'].tolist()\n",
    "    params_to_partial = {\n",
    "        k: model[k]\n",
    "        for k in [\"model\", \"collection_name\", \"model_embedding\", \"search_method\", \"limit\", \"system_prompt\", \"sampling_params\", \"model_rerank\"]\n",
    "        if model.get(k)\n",
    "    }\n",
    "    generate_with_rag_partial = partial(generate_with_rag, **params_to_partial)\n",
    "\n",
    "    # Async over the prompts\n",
    "    with concurrent.futures.ThreadPoolExecutor(max_workers=8) as executor:\n",
    "        # Map generate over pairs of (model, prompt)\n",
    "        results = list(executor.map(generate_with_rag_partial, prompts))\n",
    "\n",
    "    model_answers.append(results)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 20,
   "id": "6c0af8e8-cc10-47da-9aaf-8a102156b432",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "1000\n",
      "1000\n"
     ]
    }
   ],
   "source": [
    "for answers in model_answers:\n",
    "    print(len([x for x in answers if x.strip()]))"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "d3744c5f-cae7-427a-a765-a630e6b0f266",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Patch expset: LegalBenchRAG Evaluation v1 (111)\n"
     ]
    }
   ],
   "source": [
    "# Adding RAG model to the experiment set (patching)\n",
    "# --\n",
    "common_params = {\n",
    "    \"dataset\": dataset[\"name\"],\n",
    "    \"metrics\": [\"judge_precision\", \"output_length\"],\n",
    "    \"model\": {\"sampling_params\" : sampling_params, \"system_prompt\": system_prompt},\n",
    "    \"judge_model\": {\n",
    "        \"name\": \"mistralai/Mistral-Small-3.2-24B-Instruct-2506\", \"base_url\": ALBERT_API_URL, \"api_key\": ALBERT_API_KEY\n",
    "    },\n",
    "    \"sample\": sample,\n",
    "}\n",
    "\n",
    "grid_params = {\n",
    "    \"model\": [\n",
    "        {\n",
    "            \"aliased_name\": model[\"aliased_name\"],\n",
    "            \"name\": model[\"model\"],\n",
    "            \"system_prompt\": system_prompt,\n",
    "            \"sampling_params\": sampling_params,\n",
    "            \"output\": model_answers[i],\n",
    "        }\n",
    "        for i, model in enumerate(models)\n",
    "    ],\n",
    "}\n",
    "\n",
    "expset = {\n",
    "    \"name\" : \"LegalBenchRAG Evaluation v1\",\n",
    "    \"readme\" : \"A extensive RAG evaluation on the LegalBenchRAG dataset. See [complete me]\",\n",
    "    \"cv\": {\"common_params\": common_params, \"grid_params\": grid_params, \"repeat\": 1},\n",
    "}\n",
    "\n",
    "response = requests.patch(\n",
    "    f\"{EVALAP_API_URL}/experiment_set/{expset_id}\",\n",
    "    headers={\"Authorization\": f\"Bearer {EVALAP_API_KEY}\", \"Content-Encoding\": \"gzip\"},\n",
    "    json=expset,\n",
    ")\n",
    "resp = response.json()\n",
    "if \"id\" in resp:\n",
    "    expset_id = resp[\"id\"]\n",
    "    print(f'Patch expset: {resp[\"name\"]} ({resp[\"id\"]})')\n",
    "else:\n",
    "    print(resp)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "a973bf51-15dc-4b2f-82d8-76412ee65c94",
   "metadata": {},
   "outputs": [],
   "source": []
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "Python 3 (ipykernel)",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.13.11"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 5
}
